The franchise drug for autoimmune disorders such as dermatitis could face a challenger: A candidate from Apogee Therapeutics.

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

Apogee Therapeutics Inc. plans to enter a crowded atopic dermatitis market with established drugs, such as Dupixent (dupilumab, Regeneron Pharmaceuticals Inc. and Sanofi SA) and Ebglyss ...

Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main ...

Apogee Therapeutics said its antibody treatment alleviated signs and symptoms of atopic dermatitis far more than a placebo — ...

Sanofi’s new atopic dermatitis treatment Dupixent has gained EU approval, setting it up for a launch across key European markets. Dupixent (dupilumab) is tipped to be the market leader among a ...

Like Dupixent, which has multiple indications across five inflammatory diseases, Sanofi views amlitelimab as a “pipeline-in-a-product”, with the potential to reap sales of €5 billion ($5.4 ...

Investing.com -- Apogee (NASDAQ: APOG) Therapeutics, Inc. (NASDAQ: APGE) stock surged 24% on Monday after the clinical-stage biotechnology company announced positive 16-week data from its Phase 2 APEX ...

Some two dozen biotech developers of PROTACs, molecular glues and other types of protein-degrading drugs have sprung up over ...

Botox is a prescription drug that treats a variety of conditions, including migraine, limb spasticity, and bladder problems. Learn about common, mild, and serious side effects and how to manage them.